A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease

Figures & data

Table 1 Baseline and week 6 data for drug and placebo groups (mean ± SD). Independent sample t-tests were used to compare means. No statistically significant differences were found

	Age	Gender (m/f)	PD duration (yr)	MMSE^Citation22	UPDRS (total) Baseline	UPDRS (total) Week 6	UPDRS (motor) Baseline	UPDRS (motor) Week 6	NPI Baseline	NPI Week 6	BPRS Baseline	BPRS Week 6	Baylor scalea Baseline	Baylor scalea Week 6
Quetiapine, n =11	74 ±8	7/4	8 ± 4	24.6 ± 3.6	59.1 ± 21.0	55.2 ±16.4	31.2 ±14.1	28.2 ±12.3	15.4 ±7.4	8.4 ± 2.9	39.2 ±8.4	35 ±6.1	11.6 ± 2.7	8.3 ±2.9
Placebo, n =13	70 ±8	9/4	9 ± 5	20.8 ± 5.7	59.3 ± 26.5	56.5 ±16.3	29.0 ±16.8	30.1 ±10.4	21.5 ±11.3	12.2 ±8.3	41.5 ±6.5	39 ±6.4	11.9 ± 5.3	9.4 ±4.9

Abbreviations: BPRS, Brief Psychiatric Rating Scale; MMSE, Mini-mental State Examination; NPI, Neuropsychiatric Inventory; PD, Parkinson’s disease; SD, standard deviation; UPDRS, Unified Parkinson’s Disease Rating Scale.

Note: ^aBaylor PD hallucination scale.¹⁴

Figure 1 Kaplan-Meier Survival Plots (Time to dropout from trial against cumulative survival).

CummingsJLMegaMGrayKThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaNeurology199444230823147991117

 PubMed Web of Science ®Google Scholar

OndoWGTintnerRVoungKDDouble-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s diseaseMov Disord20052095896315800937

 PubMed Web of Science ®Google Scholar